Medtech Insight’s Cardiovascular Catch-Up highlights recent news and insights from cardiovascular device companies – big and small. Part two of this month's installment includes updates from lesser-known companies that you might have missed, including Cardiologs, Rhythm Management, LimFlow and ShockWave.

Under deal amendment, Innovent gets Asia rights to Cyramza, Retevmo and pirtobrutinib.

Derazantinib, a promising fibroblast growth factor kinase inhibitor, is one of the cancer assets the Swiss firm is preparing to sell off, either separately or in a bundle, as it focuses on anti-infectives.

Private Company Edition: Newpath Partners’ second fund totals $350m, Merck KGaA committed €600m to M Ventures, Eir Ventures raised €122.3m and Breakout Ventures has $112.5m. Recent financings were led by SOTIO ($317.5m), Odyssey ($218m), Avistone ($200m) and Acepodia ($109m).